Pfizer Inc (PFE)

Earnings normalized since Covid, and now we're on the other side. Stock went lower than it probably should have. He's been accumulating under $25 all year. Bullish catalysts around US government policy and potential partnerships. No material upgrades from analysts for 3-4 years now. Cheap. Very good dividend of ~6.7%. Pretty compelling.

There is interest starting to build in this type of company so there may be opportunity. Trades at less than 10 times earnings. There is a challenge with growth after a big success with the Covid vaccines. Also it might have overpaid for a recent acquisition although this may be necessary.. He owns Merck which has a lower valuation and more promise in the pipeline.

He wouldn't have picked it a year ago if he'd known that Mr. "Anti-Vaccine" Robert F. Kennedy was going to be given the health portfolio. Trading at 10x PE, with 6% dividend -- could be called a value trap, and people worry about the growth.

What he likes is how they took all that $$ made during Covid and reinvested it in potential growth areas, mostly in oncology. Stock hasn't shown any results yet, but they should have a better growth profile going forward. Bidding war for Metsera dragging on stock. Earnings this week were better than expected, good balance sheet. Downside protection in this market plus the dividend. Absolutely a buy down here.

Sells at 8x earnings. It lacks a growth engine, and the Seagen acquisition hasn't paid off.

It reports Tuesday. Will it break $25. Shareholders seem to be satisfied holding it for the 7% dividend. He likes growth, but this dividend seems safe, backed up by cash flow.

One of the most interesting stocks out there. One of the world's leading pharma companies. Still has a very strong research platform. Earnings have been improving due to cost-cutting. Will probably hit another homerun drug in the next few years. Yield is almost 7%, not in trouble. 

It reports Tuesday. We need to see dramatic results in its drug trials. Shareholders are getting restive. It's been a while since they bought Seagen. Who knows what Trump has up his sleeve against this industry.

Sold it a few years ago because R&D activity wasn't there, and were overpaying for companies, namely Seagen. The stock is cheap, but carries a lot of debt. Isn't sure if the dividend is secure. 

Holds it in the dividend income fund. Has a safe dividend of 6 to 6 1/2% with cash flow. Has a large pipeline of new drugs but it is difficult to predict how many or which ones will take.

Downtrend, lower highs and lower lows. Never assume that the downtrend's over until the chart proves it. Last high and last low are being taken out. If you own, wait till it rallies and then get out.

Worth taking a good, hard look at. Phenomenal yield, and he likes yield. Chart is starting to form a bit of a bottom. Low PE. Has things in the pipeline that the market's not paying for. If you're a longer-term investor, well worth sitting on it and getting rewarded while you wait for an upside pop from the drugs coming through as hoped. 

He's looking at it closely.

Laggard. Doesn't see anything in the healthcare sector that points to a turnaround in the near term. Target on the sector's back on margins. Stock's bounced over the last few weeks, use that to move on.

The problem with pharma is that their drugs all face a patent cliff. Over the last 25 years, pharma companies have tried to sustain themselves through consolidation (mergers, buying small companies). Caution: the dividend may look attractive, but that could be the result of the falling share price.

It needs a catalyst, like a new cancer formulation. Otherwise, you're just collecting that 6.75% dividend.

She likes the space but people are not investing in it. It has a low valuation and is tempting but she prefers elsewhere. It is a global leader in a crowded field. She sees 5% growth so there is some upside.